Form 4: Repligen Corp Director Barthelemy Reports Stock and Option Awards

Director Nicolas Barthelemy reports the acquisition of restricted stock units and stock options in Repligen Corp.

Summary

• On May 15, 2025, Nicolas Barthelemy, a director of Repligen Corp, reported the acquisition of 973 restricted stock units (RSUs) and 1,800 stock options.
• The RSUs represent a contingent right to receive one share of Repligen Corporation's Common Stock each and were awarded at a price of $0.
• These RSUs vest on the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders.
• The stock options have an exercise price of $123.26 and expire on May 15, 2035.
• These options also vest on the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders.
• Following these transactions, Barthelemy directly owns 4,441 shares of common stock and 1,800 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and aligns management's interests with shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders, which has not yet been determined.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Companies like Danaher, Thermo Fisher Scientific, and Sartorius also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally in line with industry standards for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs positively, as it aligns management's interests with theirs.
• Employees may see this as a sign of the company's commitment to its leadership.

Next Steps

• The director will need to report any further changes in beneficial ownership of Repligen Corp securities.
• The company will hold its next annual meeting, which could affect the vesting date of the RSUs and stock options.

Key Dates

Keywords

Repligen Corp, Director, Stock Options, Restricted Stock Units, RGEN, Form 4, Beneficial Ownership